Effect of the human immunodeficiency virus type 1 reverse transcriptase polymorphism Leu-214 on replication capacity and drug susceptibility. 2009

Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
irsiCaixa Foundation, Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain.

A negative association between polymorphism Leu-214 and type-1 thymidine analogue mutations (TAM1) and a positive association with a clinically favorable virological response to thymidine analogue-based combination antiretroviral therapy have been described. In this study, the impact of Leu-214 on replication capacity and resistance to zidovudine (ZDV) of viruses containing TAM1 or TAM2 was determined. Leu-214 decreased the growth rate of viruses bearing Tyr-215, as well as their resistance to ZDV. This observation was confirmed by structural and molecular modeling data, suggesting a regulatory role for Leu-214 in the emergence and phenotypic resistance of TAM1.

UI MeSH Term Description Entries
D007930 Leucine An essential branched-chain amino acid important for hemoglobin formation. L-Leucine,Leucine, L-Isomer,L-Isomer Leucine,Leucine, L Isomer
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014779 Virus Replication The process of intracellular viral multiplication, consisting of the synthesis of PROTEINS; NUCLEIC ACIDS; and sometimes LIPIDS, and their assembly into a new infectious particle. Viral Replication,Replication, Viral,Replication, Virus,Replications, Viral,Replications, Virus,Viral Replications,Virus Replications
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
May 1998, Journal of virology,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
January 2004, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
February 1996, Biological chemistry Hoppe-Seyler,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
October 2008, AIDS research and human retroviruses,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
August 2007, Antiviral research,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
December 2004, Antimicrobial agents and chemotherapy,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
March 2022, Natural product research,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
July 1997, Journal of virology,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
October 1991, Proceedings of the National Academy of Sciences of the United States of America,
Maria Carmen Puertas, and Maria Jose Buzón, and Anna Artese, and Stefano Alcaro, and Luis Menendez-Arias, and Carlo Federico Perno, and Bonaventura Clotet, and Francesca Ceccherini-Silberstein, and Javier Martinez-Picado
August 1999, Journal of virology,
Copied contents to your clipboard!